Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024 report and make more profitable business decisions.
Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula.
The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development market research report provide comprehensive information on the therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Proliferative Diabetic Retinopathy (NPDR) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Non-Proliferative Diabetic Retinopathy (NPDR) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Non-Proliferative Diabetic Retinopathy (NPDR) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Non-Proliferative Diabetic Retinopathy (NPDR) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Non-Proliferative Diabetic Retinopathy (NPDR) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bayer AGDaegu Gyeongbuk Medical Innovation Foundation
EyeGene Inc
EyePoint Pharmaceuticals Inc
Kato Pharmaceuticals Inc
Kubota Vision Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Ocuphire Pharma Inc
OcuTerra Therapeutics Inc
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Tarsier Pharma Ltd
Valo Health LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Non-Proliferative Diabetic Retinopathy (NPDR) reports